Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oncolysis Using Herpes Simplex Virus Type 1 Engineered to Express Cytosine Deaminase and a Fusogenic Glycoprotein for Head and Neck Squamous Cell Carcinoma

Oncolysis Using Herpes Simplex Virus Type 1 Engineered to Express Cytosine Deaminase and a... ORIGINAL ARTICLE Oncolysis Using Herpes Simplex Virus Type 1 Engineered to Express Cytosine Deaminase and a Fusogenic Glycoprotein for Head and Neck Squamous Cell Carcinoma Daniel L. Price, MD; Shu-Fu Lin, MD; Ziqun Han, MD; Guy Simpson, PhD; Robert S. Coffin, PhD; Joyce Wong, MD; Sen Li, BS; Yuman Fong, MD; Richard J. Wong, MD Objective: To determine if prodrug conversion of fluo- 3 of the 4 cell lines. Fluorocytosine did not enhance cy- GALV/CD rocytosine to fluorouracil by an engineered herpes vi- totoxicity induced by OncoVEX at a multiplicity GALV/CD rus, OncoVEX , enhances oncolytic therapy of head of infection of 0.1. However, for the least-sensitive SCC25 and neck squamous cell carcinoma. cell line, virus at a multiplicity of infection of 0.01 was cytotoxic to only 4% of cells after 6 days but was cyto- GALV/CD Design: We assessed the ability of OncoVEX and toxic to 35% of cells with fluorocytosine. GFP OncoVEX to infect, replicate within, and lyse 4 head and neck squamous cell carcinoma lines in vitro. The ef- GALV/CD Conclusions: OncoVEX efficiently infects, repli- GALV/CD fects of adding fluorocytosine with OncoVEX were cates within, and lyses head and neck squamous cell car- evaluated. cinoma at http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Otolaryngology - Head & Neck Surgery American Medical Association

Oncolysis Using Herpes Simplex Virus Type 1 Engineered to Express Cytosine Deaminase and a Fusogenic Glycoprotein for Head and Neck Squamous Cell Carcinoma

Loading next page...
 
/lp/american-medical-association/oncolysis-using-herpes-simplex-virus-type-1-engineered-to-express-LyUZbQ7Iax

References (29)

Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6181
eISSN
2168-619X
DOI
10.1001/archoto.2009.214
pmid
20157061
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Oncolysis Using Herpes Simplex Virus Type 1 Engineered to Express Cytosine Deaminase and a Fusogenic Glycoprotein for Head and Neck Squamous Cell Carcinoma Daniel L. Price, MD; Shu-Fu Lin, MD; Ziqun Han, MD; Guy Simpson, PhD; Robert S. Coffin, PhD; Joyce Wong, MD; Sen Li, BS; Yuman Fong, MD; Richard J. Wong, MD Objective: To determine if prodrug conversion of fluo- 3 of the 4 cell lines. Fluorocytosine did not enhance cy- GALV/CD rocytosine to fluorouracil by an engineered herpes vi- totoxicity induced by OncoVEX at a multiplicity GALV/CD rus, OncoVEX , enhances oncolytic therapy of head of infection of 0.1. However, for the least-sensitive SCC25 and neck squamous cell carcinoma. cell line, virus at a multiplicity of infection of 0.01 was cytotoxic to only 4% of cells after 6 days but was cyto- GALV/CD Design: We assessed the ability of OncoVEX and toxic to 35% of cells with fluorocytosine. GFP OncoVEX to infect, replicate within, and lyse 4 head and neck squamous cell carcinoma lines in vitro. The ef- GALV/CD Conclusions: OncoVEX efficiently infects, repli- GALV/CD fects of adding fluorocytosine with OncoVEX were cates within, and lyses head and neck squamous cell car- evaluated. cinoma at

Journal

JAMA Otolaryngology - Head & Neck SurgeryAmerican Medical Association

Published: Feb 1, 2010

There are no references for this article.